Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00315380 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary and study completion dates: Apr 2024 to Dec 2028Enrollment target: 500 to 700 · Site contacts updated at 1 of 10 sites · Collaborators: 1 to 2 · 1 morev36Show 4 more changesShow less
NotablePrimary and study completion dates: Apr 2020 to Apr 2024Eligibility criteria shortened, about 83 words · Study description shortened, about 29 words · Site details revised at 3 of 8 sites · 1 morev31Show 4 more changesShow less
NotablePrimary and study completion dates: Apr 2019 to Apr 2020v29
MinorRe-verified, no change to tracked fieldsv28
MinorSite contacts updated at 1 of 8 sitesv27
MinorSite contacts updated at 1 of 8 sitesv26
MinorSite contacts updated at 3 of 8 sitesv25
MinorSite contacts updated at 1 of 8 sitesv24
NotableEnrollment target: 250 to 500Site contacts updated at 1 of 8 sitesv23Show 1 more changeShow less
Site contacts updated at 1 of 8 sites
NotablePrimary and study completion dates: Apr 2016 to Apr 2019Site contacts updated at 2 of 8 sitesv22Show 1 more changeShow less
Site contacts updated at 2 of 8 sites
MinorSite contacts updated at 1 of 8 sitesv21
MinorSite contacts updated at 2 of 8 sitesv20
MinorStudy sites: 9 to 8Study description revised · Eligibility criteria expanded, about 3 words · Study title expanded, about 3 wordsv19Show 3 more changesShow less
NotableLead sponsor: Boston University to University of PennsylvaniaStudy sites: 8 to 9v17Show 1 more changeShow less
Study sites: 8 to 9
MinorSite contacts updated at 2 of 8 sitesv16
NotableLead sponsor: Office of Rare Diseases (ORD) to Boston UniversityEnrollment target: 96 to 250 · Primary completion date: Apr 2011 to Apr 2016 · Study sites: 6 to 8 · 3 morev15Show 6 more changesShow less
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.